Cadila Launches Tarzed For Early-stage Breast Cancer
24th Jan, 2022 | NewsCadila Pharmaceuticals has launched trastuzumab under the brand name Tarzed. It is a humanized monoclonal antibody and is recommended for HER2-positive early-stage breast cancer and metastatic breast cancer.
Navjeevan Express
India News Republic
Health Vision
Free Express
ET Healthworld
ET Express Pharma
Bio Voice
Prabhat
Suger Mint
Array
(
[PHPSESSID] => 3eb181157be82b185dabed4fa5b518bb
)
To give you the best possible experience every time you visit our site, we use cookies to identify and store your preferences on your browser. Continuing to browse our site means that you are "ok" with this. Learn more about our privacy policy.
Okay